A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

Trial Profile

A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Caffeine (Primary) ; Capmatinib (Primary) ; Midazolam (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 21 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
    • 11 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top